Michael Kragh

This inventor holds 14 USPTO granted patents and 6 published patent applications, plus 6 CIPO patents and 8 EPO patents. Top assignees: Symphogen A/s, Les Laboratoires Servier, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Kragh. Retrieved from https://idiyas.com/inventor/michael-kragh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 6)

% Patents Active = 64.3

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 6.7

ph-index = 3

Forward Citations = 26(Granted Patents)

Company Filing History:

Les Laboratoires Servier

patents

1 out of 121

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

patents

4. 1 out of 1

Københavns Universitet

patent

Years Active: 2004-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577302 - ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS (2026-03-17),

2. 12030942 - Anti-PD-1 antibodies and compositions (2024-07-09),

3. 11939380 - Combination therapies targeting PD-1, TIM-3, and LAG-3 (2024-03-26),

4. 11834503 - Anti-lag-3 antibodies and compositions (2023-12-05),

5. 11390676 - Anti-LAG-3 antibodies and compositions (2022-07-19),

6. 11390674 - Anti-TIM-3 antibodies and compositions (2022-07-19),

7. 11034765 - Anti-PD-1 antibodies and compositions (2021-06-15),

8. 10450376 - Anti-MET antibodies and compositions (2019-10-22),

9. 10221246 - Pan-HER antibody composition (2019-03-05),

10. 10058610 - Methods for treating cancer by administering humanized pan-HER antibody compositions (2018-08-28),

11. 9527913 - Humanized pan-HER antibody compositions (2016-12-27),

12. 9155802 - Pan-HER antibody composition (2015-10-13),

13. 8663640 - Methods using recombinant anti-epidermal growth factor receptor antibody compositions (2014-03-04),

14. 6701171 - Method and apparatus for non-invasive detection of angiogenic and anti-angiogenic activity in living tissue (2004-03-02),

Title: Michael Kragh: Innovator in Antibody Therapies

Introduction

Michael Kragh is a prominent inventor based in Copenhagen, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of antibody therapies. With a total of 13 patents to his name, Kragh is recognized for his innovative approaches to treating diseases related to PD-1 activity, including cancer.

Latest Patents

Among his latest patents are the "Anti-PD-1 antibodies and compositions," which focus on the use of anti-PD-1 antibodies in treating diseases associated with PD-1 activity. This invention aims to provide new methods for combating cancer. Another notable patent is for "Combination therapies targeting PD-1, TIM-3, and LAG-3." This disclosure outlines therapies that utilize antibodies specific to these targets, enhancing immunity in patients and offering potential treatments for various cancers.

Career Highlights

Throughout his career, Michael Kragh has worked with notable companies such as Symphogen A/S and Les Laboratoires Servier. His work in these organizations has contributed to advancements in therapeutic strategies and the development of innovative treatments.

Collaborations

Kragh has collaborated with several professionals in his field, including Mikkel Wandahl Pedersen and Klaus Koefoed. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Michael Kragh's contributions to antibody therapies and his innovative patents highlight his role as a leading inventor in the biotechnology sector. His work continues to influence the development of treatments for serious diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.